RLS Global introduces ChloraSolv in the veterinary care segment in Scandinavia
RLS Global’s strategic focus is to expand its technical platform, buffered hypochlorite technology, to new indications, applications and geographical areas. Today, RLS Global can announce a strategic partnership with Swevet in the animal care segment for Sweden, Norway and Denmark.
During the second half of 2022, RLS Global will review the alternatives to establish distribution networks for the animal care segment in the rest of Europe and the Middle East.
RLS Global has established relationships with animal hospitals within the large international animal care groups Anicura and Evidensia, clinics that are now ready to start using ChloraSolv in their treatments of hard to heal wounds.
Together with veterinarians, RLS Global has evaluated ChloraSolv in the treatment of hard to heal wounds in dogs, cats and horses. As the results are very positive, RLS Global is now establishing a Scandinavian distribution network through an exclusivity agreement with Swevet. Swevet is Sweden’s only full-range wholesaler when it comes to animal health and works closely with veterinarians and other staff at animal care clinics to support them in their business with knowledge and products.
“The animal segment is a new market and revenue stream for us”, says Karin Fischer, CEO, RLS Global. “But the principal of wound healing is similar for animals as for humans, so we are convinced that ChloraSolv will provide great benefit in this segment.”
“Hard to heal wounds that require prolonged treatments, increase the suffering for the animal, but also the costs for the animal owner. In worst case, it can lead to amputation or to having to put the animal down.”
Hard to heal wounds are a reality in animal health, as well as in the human care. Wounds can be caused by everything from shards of glass and other sharp objects, to fights and bites and are also linked to diabetes. Healing can be made more difficult by bacteria and dirt from the outside or the animal licking the wound.
THIS IS CHLORASOLV
ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.1 ChloraSolv does not damage healthy tissue and is well tolerated by the patient.
- Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. An open single arm multicenter pilot investigation to evaluate the debriding effect of amino acid buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during six weeks treatment. Journal of Wound Care (Accepted for publication).
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012–2017, the company was listed on Aktietorget.
FOR MORE INFORMATION, PLEASE CONTACT:
Karin Fischer, CEO, RLS Global
E-mail: karin.fischer@rlsglobal.se
Tel: +46 702 48 46 51
ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products for some of our most common diseases in wound and dental care. RLS has a portfolio of strong brands, including ChloraSolv® and Carisolv®.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS intends to work with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global